Cardiac amyloidosis (CA), once thought to be a rare disease, is increasingly recognized due
to enhanced clinical awareness and better diagnostic imaging. CA is becoming of …

In this update, we focus on selected topics of high clinical relevance for health care
providers who treat patients with heart failure (HF), on the basis of clinical trials published …

Transthyretin (TTR) amyloidosis (ATTR amyloidosis) is a multisystemic, multigenotypic
disease resulting from deposition of insoluble ATTR amyloid fibrils in various organs and …

Cardiac amyloidosis (CA) is an infiltrative and restrictive cardiomyopathy that leads to heart
failure, reduced quality of life, and death. The disease has two main subtypes, transthyretin …

Systemic amyloidosis encompasses a debilitating, under-diagnosed but increasingly
recognized group of disorders characterized by the extracellular deposition of misfolded …

Purpose Cardiac amyloidosis, a restrictive heart disease with high mortality and morbidity, is
underdiagnosed due to limited targeted diagnostic imaging. The primary aim of this study …

Amyloid light chain (AL) amyloidosis is a systemic disease characterised by the aggregation
of misfolded immunoglobulin light chain (LC), predominantly in the heart and kidneys …

Transthyretin-cardiac amyloidoses (ATTR-CA) are an underdiagnosed but increasingly
recognized cause of heart failure. Extracellular deposition of fibrillary proteins into tissues …

The classes of recommendations and levels of evidence in these guidelines were
determined and described according to the “Guidelines for the treatment of acute and …

Background Non-invasive cardiac imaging allows detection of cardiac amyloidosis (CA) in
patients with aortic stenosis (AS). Our objective was to estimate the prevalence of clinically …